Introduction
Pulmonary arterial hypertension (PAH) is a progressive disease with poor survival. PAH is classified by the 2009 updated clinical classification of pulmonary hypertension and a major subgroup is PAH due to congenital heart disease (CHD) with systemic-to-pulmonary shunt [1] . This shunting may lead to extensive histological changes in the distal pulmonary arteries resulting in an irreversible increase in pulmonary vascular resistance (PVR). The classification of CHD-PAH includes four categories: (1) Eisenmenger syndrome, (2) PAH associated with systemicto-pulmonary shunts, (3) PAH with small septal defects, and (4) PAH after corrective cardiac surgery [2] . In these patients advanced pharmacological therapy should be considered.
Three classes of advanced therapy for PAH are currently in use: prostanoids such as epoprostenol, endothelin-1 receptor antagonists such as bosentan, and phosphodiesterase 5 inhibitors such as sildenafil [3] . Bosentan has been shown to improve 6-min walking distance (6MWD) and to decrease PVR in patients with Eisenmenger syndrome [4] . Anecdotal experience with the phosphodiesterase type-5 inhibitors sildenafil and tadalafil show favourable functional and haemodynamic results in patients with CHD-PAH [5, 6] . We present three patients treated with advanced pharmacological therapy for CHD-PAH: a patient with Eisenmenger syndrome receiving standard care, a patient with atrial septal defect receiving advanced therapy as a bridge to surgery, and a patient with segmental PAH who was started on advanced therapy empirically.
Case 1: an Eisenmenger patient
The first case describes a 38-year-old male patient with a double inlet left ventricle, hypoplastic aortic arch and patent ductus arteriosus. He was deemed ineligible for a Fontan circulation and developed PAH in childhood. He was severely symptomatic (NYHA functional class III-IV) and could only live a sedentary lifestyle. He had been on the waiting list for combined heart and lung transplantation for 2 years. He was cyanotic with a peripheral saturation of 80%. His haemoglobin level was 13.4 mmol/L. On auscultation, normal heart sounds were heard, as well as a systolic murmur grade II/VI. Trans-thoracic echocardiography (TTE) showed a moderate systolic ventricular function, mild mitral regurgitation, and moderate tricuspid regurgita-tion (Fig. 1) . His 6MWD was 475 m, and during exercise his saturation dropped from 80% to 62%
It was decided to initiate bosentan 125 mg twice daily, as monotherapy. He improved to NYHA functional class II and his six 6MWD increased from 475 to 500, 517 and 557 m at 1, 2 and 3 years, respectively. His saturation remained unchanged. Clinically he has improved over the past 4 years on bosentan monotherapy and is now able to work 12 h a week. He could be removed from the transplantation list.
Case 2: advanced therapy as a bridge to atrial septal defect closure A 25-year-old female patient was referred to our hospital because of progressive dyspnoea for 5 months. Her medical history was unremarkable, and auscultation revealed fixed splitting of the second heart sound. The ECG showed sinus tachycardia of 120 beats/min, right heart axis, and tall R waves in V1 and V2. The chest x-ray showed a dilated right pulmonary artery and pulmonary trunk. A CT scan was performed to rule out pulmonary embolism. Pulmonary embolism was not observed, but the right ventricle and pulmonary trunk were severely dilated. In addition, an anomalous connection of the right upper pulmonary vein to the superior caval vein was found. TTE revealed a small left ventricle with good systolic function. The right ventricle was dilated with poor systolic function. The interventricular septum was flattened during both diastole and systole, suggesting right-sided pressure overload. Agitated saline contrast injection revealed shunting from the right to left atrium, suggestive of an atrial septal defect. Transoesophageal echocardiogram (TEE) showed a sinus venosus defect with a right-to-left shunt (Fig. 2) . Right heart catheterisation demonstrated a pulmonary arterial pressure (PAP) of 89/46 mmHg (mean 55 mmHg) with a systemic blood pressure of 118/65 mmHg (mean 82 mmHg). PVR was markedly elevated at 680 dynes/ s/cm −5 (8.5 Wood Units). Epoprostenol infusion to achieve maximal pulmonary vascular dilation did not result in a reduction of PVR. Her baseline 6MWD was 514 m and saturation dropped from 97% at rest to 78% during exercise. The working diagnosis at that time was PAH associated with systemic-to-pulmonary shunt (Group 2). However, given the unusually severe PAH for a patient with sinus venosus defect at this age, we could not rule out that the clinical picture was explained by a combination of idiopathic pulmonary arterial hypertension (IPAH, formerly called primary pulmonary hypertension) and a sinus venosus defect. This patient was treated with combination therapy of bosentan 125 mg twice daily and sildenafil 20 mg three times daily. After several weeks of therapy, subjective improvement was observed. After 3 months of treatment, repetition of the right heart catheterisation showed that the PAP had dropped to 62/32 mmHg (mean 42 mmHg) with a systemic blood pressure of 104/54 mmHg (mean 73 mmHg). In addition, her 6MWD increased from 514 to 640 m, NT-pro-BNP decreased from 1092 to 497 ng/L, and saturation during exercise increased from 78% to 90%. Because of the beneficial response to medical therapy, this patient was planned for closure of the sinus venosus defect and rerouting of the pulmonary vein flow to the left atrium. The interatrial septum will be reconstructed with a fenestrated patch to facilitate complete closure via percutaneous intervention at a later stage. This 'staged' procedure was chosen to minimise the risk of acute right-sided heart failure, which is a life-threatening complication.
Case 3: advanced therapy in a patient with segmental PAH started empirically
The third case describes a 39-year-old female patient who presented with shortness of breath. She had a history of pulmonary atresia, ventricular septal defect and stenosis of a major aortopulmonary collateral artery (MAPCA) to the right inferior pulmonary lobe (Fig. 3 ). In childhood she had initially been palliated with a left-sided Blalock-Taussig shunt to supply pulmonary blood flow, and later with a central Goretex shunt. New cardiac evaluation followed in adolescence. At that time further surgical repair was not indicated, because of her stable cardiac situation and the risk of complications associated with a reoperation. The pulmonary lobes supplied by the aorta-pulmonary shunt or the non-stenosed MAPCAs experienced a systemic blood pressure and developed PAH, whereas the right inferior lobe supplied by the stenosed MAPCA experienced a relatively normal PAP and as a consequence did not develop PAH. The term segmental PAH has been suggested to describe this situation. She was cyanotic with a peripheral saturation of 81%. No pathological murmurs were heard at auscultation. Her NT-pro-BNP was 419 ng/L. Echocardiographically, her right and left ventricular systolic function were good. Her 6MWD was 462 m and saturation dropped from 81% to 65% at exercise.
Because of her shortness of breath, it was decided to treat this patient empirically with bosentan 125 mg twice daily as monotherapy. After initiation, clinical improvement was observed. Her 6MWD increased from 462 to 478, 502 and 513 m at 1, 2 and 3 years respectively. After 3 years of treatment saturation at rest increased to 85%, and NT-pro-BNP decreased to 334 ng/L. Clinically she improved to mild shortness of breath. She experiences fatigue occasionally. 
Discussion
We describe three adults where advanced pharmacological therapy for CHD-PAH was prescribed in different clinical settings. The first patient, diagnosed with Eisenmenger syndrome, was treated according to current guidelines [7] . In the second patient, therapy was started more aggressively as a bridge to atrial septal defect closure. The third patient with segmental PAH was started on advanced therapy empirically.
Presentation with Eisenmenger syndrome, as in the first patient, has a negative impact on survival. Eisenmenger syndrome patients are highly symptomatic, and require major lifestyle adjustments due to limited functional capacity. Quality of life is diminished and pregnancy is strictly contraindicated [8] . In our extended experience with a nationwide standardised protocol on advanced treatment in CHD-PAH, a prolonged beneficial effect of bosentan treatment on 6MWD, echocardiographic stroke volume and quality of life in patients with Eisenmenger syndrome has been shown [9] . In patients with additional Down syndrome stabilisation was seen [9] . The 6MWD is associated with clinical outcome and prognosis [10] . In the second patient optimisation with advanced therapy led to eligibility for surgical closure. The decision to proceed with surgery was made, regardless of the persistent high mean PAP, on the basis of reversibility in PVR after 3 months of advanced medical treatment. Patients with septal defects initially ineligible for cardiac surgery due to severe PAH could benefit from advanced therapy as a bridge to surgical intervention. Patients with segmental PAH, such as our patient in case three, are rare. Segmental PAH is often due to post-surgical pulmonary artery stenosis, resulting in local differences in pulmonary artery pressure and severity of the pathophysiological changes in the pulmonary circulation. Our group has reported on several cases with segmental PAH demonstrating improvement of NYHA functional class and exercise capacity after 12 months of bosentan treatment [11] .
Also in other patient categories, evidence on beneficial effect of advanced therapy is increasing. In NYHA functional class II PAH patients, short-term efficacy of bosentan has been demonstrated [12] . However, this study included only 16 patients with CHD-PAH.
Another group of patients who might benefit from advanced therapy are those with a Fontan circulation. In Fontan patients' plasma endothelin-1 level has been shown to be elevated [13] . Endothelin-1 induces pulmonary vasoconstriction, and increases PVR. Low PVR is crucial for a well-functioning Fontan circulation, and endothelin-1 receptor antagonists might therefore contribute to improvement of clinical status in these patients. We are currently performing a prospective randomised trial on bosentan in Fontan patients; the results are expected in spring 2012 [14] .
Finally, advanced therapy might be useful in CHD patients who undergo cardiac surgery, who tend to have a decline in right ventricular function [15] . Treatment with an endothelin-1 receptor antagonist might reduce perioperative pulmonary vasoconstriction induced by the endothelin-1 release initiated by the cardiopulmonary bypass [16] . In a small study, perioperative treatment with a selective endothelin-1 receptor antagonist led to a significant decrease in PVR compared with the control group [17] . However, trials are needed to confirm this hypothesis and to show clinical benefit in CHD patients. In our centre we are
A B
Posterior view Anterior view Fig. 3 Segmental pulmonary arterial hypertension in case 3. a Magnetic resonance angiography demonstrating left inferior MAPCA stenosis, b Schematic drawing currently evaluating the effect of bosentan on perioperative right ventricular function prospectively.
Conclusion
CHD-PAH remains a severe disease, leading to reduced quality of life and cardiac complications including right ventricular failure, arrhythmias and premature death. Our cases demonstrate the variety of indications in which advanced therapy is justified. Research is warranted in CHD patients with elevated endothelin-1 levels, who are at risk of increase in pulmonary artery pressure, to determine whether these patients benefit of advanced therapy.
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